
US regulators have warned doctors and patients about the risk of severe liver injury associated with Sanofi-Aventis’ atrial fibrillation (AF) …

NICE has given a restricted approval to Sanofi-Aventis’s Multaq as a second line treatment for atrial fibrillation patients. The guidance …
In its final draft guidance, UK cost-effectiveness body NICE has reaffirmed its previous positive opinion to recommend the limited use …

